株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

筋萎縮性側索硬化症:世界の治験動向

Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 239400
出版日 ページ情報 英文 203 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
筋萎縮性側索硬化症:世界の治験動向 Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017
出版日: 2017年03月31日 ページ情報: 英文 203 Pages
概要

当レポートでは、筋萎縮性側索硬化症治療薬に関する治験の最新動向について分析しており、G7 (主要7カ国) 諸国およびE7 (新興7カ国) における治験件数、被験者数、有望なスポンサー、治験に携わっている主な企業や機関、有望な薬剤の情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系疾患治療薬の治験における筋萎縮性側索硬化症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系疾患治療薬の治験における筋萎縮性側索硬化症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

筋萎縮性側索硬化症治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials 32
  • Prominent Drugs 34
  • Latest Clinical Trials News on Amyotrophic Lateral Sclerosis 35
  • Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 35
  • Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 35
  • Mar 01, 2017: BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn Available to Patients as a Hospital Exemption Product 35
  • Feb 27, 2017: BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success 36
  • Feb 16, 2017: City of Hope to Manufacture NurOwn for Brainstorm's Phase 3 ALS Clinical Trial 36
  • Feb 08, 2017: Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS 37
  • Jan 30, 2017: BrainStorm Announces Validation of NurOwn Cryopreservation Process 37
  • Jan 24, 2017: Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases 37
  • Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 37
  • Clinical Trial Profile Snapshots 39

Appendix 201

  • Abbreviations 201
  • Definitions 201
  • Research Methodology 202
  • Secondary Research 202
  • About GlobalData 203
  • Contact Us 203
  • Source 203

List of Tables

List of Tables

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures

List of Figures

  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Amyotrophic Lateral Sclerosis T
Back to Top